Securities Fraud Investigation Into Biohaven Ltd. (BHVN) Announced – Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm
IF YOU ARE AN INVESTOR WHO LOST MONEY ON BIOHAVEN LTD. (BHVN), CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING CLAIMS TO RECOVER YOUR LOSS.
What Happened?
On July 17, 2023, Biohaven disclosed that the FDA had rejected the New Drug Application ('NDA') for its spinocerebellar ataxia ('SCA') treatment, troriluzole, having refused to even review the application after the Phase 3 SCA Trial had failed to meet its primary endpoint. On this news, Biohaven's stock price fell $5.38, or 22.6%, to close at $18.42 per share on July 27, 2023, thereby injuring investors.
Then, on March 3, 2025, Biohaven released its fourth quarter and full year 2024 financial results, disclosing that recent data from a late-stage study of its BHV-7000 treatment for bipolar mania 'did not statistically separate from the comparator on the Young Mania Rating Scale primary outcome measure[.]' On this news, Biohaven's stock price fell $5.12, or 13.8%, to close at $32.06 per share on March 3, 2025.
Then, on April 25, 2025, news reports emerged that, according to the European Medicines Agency ('EMA'), Biohaven had withdrawn its Marketing Authorization Application ('MAA') for troriluzole in late March 2025. On this news, Biohaven's stock price fell $3.56, or 15.2%, to close at $19.84 per share on April 25, 2025.
Then, on May 14, 2025, Biohaven announced that 'the Division of Neurology 1 within FDA's Office of Neuroscience informed the Company that they are extending the [Prescription Drug User Fee Act ('PDUFA')] date for the troriluzole [NDA] for the treatment of [SCA] by three months to provide time for a full review of Biohaven's recent submissions related to information requests from the FDA,' and that '[t]he Division also informed Biohaven that it is currently planning to hold an advisory committee meeting to discuss the application, but no date has been scheduled.' On this news, Biohaven's stock price fell $3.84, or 19.5%, to close at $15.82 per share on May 15, 2025, thereby injuring investors further.
Contact Us To Participate or Learn More:
If you wish to learn more about this action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact us.
Charles Linehan, Esq.,
Glancy Prongay & Murray LLP,
1925 Century Park East, Suite 2100,
Los Angeles California 90067
Email: shareholders@glancylaw.com
Telephone: 310-201-9150 (Toll-Free: 888-773-9224)
Visit our website at www.glancylaw.com.
Follow us for updates on LinkedIn, Twitter, or Facebook.
Whistleblower Notice
Persons with non-public information regarding Biohaven should consider their options to aid the investigation or take advantage of the SEC Whistleblower Program. Under the program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Charles H. Linehan at 310-201-9150 or 888-773-9224 or email shareholders@glancylaw.com.
About Glancy Prongay & Murray LLP
Glancy Prongay & Murray LLP ('GPM') is a premier law firm representing investors and consumers in securities litigation and other complex class action litigation. GPM has been consistently ranked in the Top 50 Securities Class Action Settlements by ISS Securities Class Action Services. In 2018, GPM was ranked a top five law firm in number of securities class action settlements, and a top six law firm for total dollar size of settlements.
With four offices across the country, GPM's nearly 40 attorneys have won groundbreaking rulings and recovered billions of dollars for investors and consumers in securities, antitrust, consumer, and employment class actions. GPM's lawyers have handled cases covering a wide spectrum of corporate misconduct and relating to nearly all industries and sectors. GPM's past successes have been widely covered by leading news and industry publications such as The Wall Street Journal, The Financial Times, Bloomberg Businessweek, Reuters, the Associated Press, Barron's, Investor's Business Daily, Forbes, and Money.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
6 minutes ago
- Yahoo
International Business Machines Corporation (IBM): Don't Abandon The Stock, Warns Jim Cramer
We recently published . International Business Machines Corporation (NYSE:IBM) is one of the stocks Jim Cramer recently discussed. International Business Machines Corporation (NYSE:IBM) is one of Cramer's favorite technology stocks. Throughout this year, the CNBC TV host has expressed optimism about the firm's CEO and the firm's consistency in winning contracts for its enterprise computing business. International Business Machines Corporation (NYSE:IBM)'s shares fell by 7.6% after the firm's latest earnings report saw software revenue of $7.39 billion miss analyst estimates of $7.43 billion. Cramer discussed the earnings report: 'Most of the news is good this morning, IBM. I still think not as bad, uh, Chipotle we have to talk about. Copyright: believeinme33 / 123RF Stock Photo Previously, he discussed potential future International Business Machines Corporation (NYSE:IBM) share price movement: 'Oh, I like IBM very much. I mentioned Ben Wright earlier. I think that Ben, he's really turned me on to this stock. We did a very positive piece about it. I think it goes, I'm going to say not much higher but creeping higher over time, and that's actually a great place to be. So I like IBM.' While we acknowledge the potential of IBM as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the . READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey.
Yahoo
6 minutes ago
- Yahoo
Northrop Grumman Corporation (NOC) Has Strong Worldwide Sales, Says Jim Cramer
We recently published . Northrop Grumman Corporation (NYSE:NOC) is one of the stocks Jim Cramer recently discussed. Northrop Grumman Corporation (NYSE:NOC) is a well-known defense contractor with a presence in the aircraft and missile industries. Its shares have gained 22% year-to-date, helped in large part by an 11% jump in July. Northrop Grumman Corporation (NYSE:NOC)'s stock soared due to its second-quarter earnings report, which saw the firm raise its midpoint full-year profit-per-share forecast to $25.20 from an earlier $25.15. The firm's $10.35 billion in revenue also beat analyst estimates of $10.07 billion. In his previous remarks about Northrop Grumman Corporation (NYSE:NOC), Cramer called the firm catastrophic after its Q1 results. This time, he struck a different tone: 'And Northrop Grumman, for worldwide sales. So we're seeing a lot of bifurcation in a lot of different industries.' Here's what Cramer said about Northrop Grumman Corporation (NYSE:NOC) after its Q1 results: 'Finally, there's Northrop Grumman, which was the dud of the day, reporting a severe top and bottom line miss for the first quarter, and cutting its full year earnings forecast pretty substantially. Now there's some important context here. Both the miss and the forecast cut were related to Northrop Grumman's next-generation B-21 bomber program. They're taking a hit on the higher cost as they try to ramp up production. Photo by NASA on Unsplash That said, even if you add that back, the impact from the B-21 charge, Northrop Grumman still would've missed the sales and earnings estimate. It just would've been a smaller disappointment. These Northrop Grumman results simply weren't up to snuff, so the stock had its worst day since 2008 today, falling $67 or nearly 13%. This one's now in the penalty box.' While we acknowledge the potential of NOC as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the . READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey.
Yahoo
6 minutes ago
- Yahoo
Dow Inc. (DOW): Good News About Industrial Economy Isn't Helping, Says Jim Cramer
We recently published . Dow Inc. (NYSE:DOW) is one of the stocks Jim Cramer recently discussed. Dow Inc. (NYSE:DOW) is one of the largest chemical companies in America. The firm's shares have lost 35% year-to-date, primarily on the back of a massive 26% selloff in April after President Trump announced his Liberation Day tariffs. Dow Inc. (NYSE:DOW)'s shares suffered another setback in July after they dipped by 17.5% after the firm's latest earnings report, which saw the firm guide third quarter sales at $10.2 billion, which was lower than analyst estimates of $10.6 billion. Dow Inc. (NYSE:DOW) also slashed its dividend, and here's what Cramer said about the firm after the disastrous earnings report: 'But then, Dow Chemicals, just, Dow, no longer Dow Chemicals. The chemicals are bad. The plastic is bad. So Jim Fitterling had to cut the dividend. I had said that this could happen. I didn't want it. But it's lower for longer, for three years, it's a very unusual negative cycle. And I've got to tell you, for all the good news we hear about the industrial economy, it's not helping. Previously, the CNBC TV host commented on Dow Inc. (NYSE:DOW)'s dividend yield: '9%, see I looked at that today. There were a bunch of guys who cut the price targets. I said to myself, wow, 9%… I have to take a pass because it means that there's something awry.' While we acknowledge the potential of DOW as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the . READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey.
